Upon joining Agilent's Board of Directors on May 1, 2024, McDonnell will become company's President and CEO. In an exclusive interaction with BioSpectrum Asia, both outgoing and incoming CEOs shared their vision for strengthening the life-science potential during their recent visit to the Asia Pacific hub in Singapore.
How is Agilent advancing cell and gene therapy modalities to enable next-gen therapeutics and applications? What are Agilent's strategies for further stabilising its footprint in APAC?
Mike McMullen: Agilent has always been ahead of the curve and aligned with the latest trends in the bioscience industry. The company has achieved a global footprint in life sciences, diagnostics, and applied markets with sales offices, logistics centres, and manufacturing facilities in three major regions. In 2015, Agilent spun off key parts of its operation to become a purely biotechnology company. After acquiring Seahorse Bioscience for $235 million in 2015, Agilent then acquired BioTek Instruments in 2019, & subsequently integrated with Seahorse Bioscience. Together, these three interdisciplinary portfolios give us a very complementary suite of technologies for analysis of cell metabolism & functions. These technologies are likely to be in high demand. Ultimately, Agilent Singapore remains a key operational zone with important investments, especially in the development of new modalities, such as CAR-T cells. Furthermore, in September 2023, Agilent Technologies signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), to develop cell-based therapy advancement. The collaboration aims to boost the nation’s role as a leading cell & gene-therapy manufacturer & clinical services enabling translational research & development.
This story is from the BioSpectrum Asia May2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia May2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.
